Comparative Pharmacology
Head-to-head clinical analysis: ACULAR versus NEVANAC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ACULAR versus NEVANAC.
ACULAR vs NEVANAC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) enzymes, reducing prostaglandin synthesis, which decreases inflammation, pain, and fever.
Nepafenac is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) enzymes, primarily COX-2, reducing prostaglandin synthesis and thereby suppressing ocular inflammation and pain.
One drop of 0.5% ophthalmic solution into the affected eye(s) four times daily.
One drop of 0.1% ophthalmic suspension instilled into the affected eye(s) three times daily.
None Documented
None Documented
Terminal half-life: 1.8 hours (ketorolac tromethamine); clinical context: short half-life supports dosing every 6 hours for acute pain, but prolonged in elderly or renal impairment (↑ to 5-6 hours, thus dose reduction required).
The terminal elimination half-life of nepafenac is approximately 12.5 hours in plasma, while its active metabolite amfenac has a half-life of about 24 hours. This supports twice-daily dosing.
Renal: ~80% as unchanged drug and glucuronide conjugates; biliary/fecal: ~20%
Nepafenac is extensively metabolized, primarily via hydrolysis to amfenac. Renal excretion accounts for approximately 85% of the administered dose, with about 13% excreted as unchanged nepafenac and amfenac in urine. Fecal elimination is minimal.
Category C
Category C
NSAID Ophthalmic
NSAID Ophthalmic